NEW YORK (GenomeWeb News) – Trovagene announced late on Tuesday the pricing of a public offering of 1.15 million units and said that its shares will begin trading on the Nasdaq Capital Market today under ticker symbol "TROV".

In connection with its listing on the Nasdaq, the San Diego-based molecular diagnostics firm has effected a one-for-six reverse stock split.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.